Topical Hemostat Market Report Scope & Overview:

The topical hemostat market size was valued at USD 5.74 billion in 2024 and is expected to reach USD 11.74 billion by 2032, growing at a CAGR of 9.37% over the forecast period of 2025-2032. 

The global topical hemostat market is growing with the increasing number of surgical procedures being performed in different parts of the globe, which continues to get complex as patients require effective bleeding control. Moreover, the aging population also pushes demand as elderly individuals will require surgeries for their long-term conditions. It drives the market expansion due to the growing need for effective hemostatic solutions and defines the topical hemostat market trend by innovation and expanding applications, both within developed and emerging healthcare systems.

For instance, in March 2025, the global population aged 65+ grew by 4.8% in 2025, driving a 7% rise in surgeries needing advanced topical hemostats.

Key Topical Hemostat Market Trends

• Rising demand for rapid, minimally invasive hemostasis in surgeries to reduce blood loss and complications.

• Use of advanced biomaterials and bioactive agents, including collagen, gelatin, chitosan, and fibrin, to enhance clotting, support tissue regeneration, and improve wound healing.

• Adoption of versatile formats, including sprays, gels, patches, and foams for easier application and better precision across surgical procedures.

• Focus on high-risk patients, including those with bleeding disorders, cardiovascular issues, or trauma, driving higher product utilization.

• Expansion of hospital procurement and distribution networks globally, especially in North America, Europe, and Asia-Pacific, to meet rising surgical demand.

• Shift toward AI-assisted surgical planning and digital monitoring to personalize hemostasis strategies, improve efficiency, and enhance patient safety.

Topical Hemostat Market Report Highlights

The U.S. topical hemostat market was valued at USD 1.78 billion in 2024 and is expected to reach USD 3.59 billion by 2032, growing at a CAGR of 9.17% over 2025-2032. The U.S. dominates the topical hemostat market in 2025, with high healthcare spending, advanced healthcare infrastructure, high surgical procedure volume, strong R&D investment capacity, with wide acceptance of innovative hemostatic products in North American hospitals. Moreover, acceptance of reimbursement coverage and an increase in awareness among healthcare professionals boost the market. This renders the US a significant region in the topical hemostat market analysis, representing strong market expansion and technological innovation.

Topical Hemostat Market Growth Drivers:

• Preference for Minimally Invasive Surgeries is Driving the Topical Hemostat Market Growth

Increasing inclination toward minimally invasive surgeries fuels the topical hemostat market share. Ensuring rapid and effective bleeding control to shorten operative times, hospitalization, and recovery is crucial for these procedures. Topical hemostats are useful for laparoscopic and robotic surgeries because they can be applied easily with expedited hemostasis. This trend is dilating their acceptance in surgical specialties globally.

For instance, in February 2025, the American College of Surgeons reported a 9% increase in US laparoscopic and robotic surgeries in 2025, boosting topical hemostat adoption.Top of Form

Topical Hemostat Market Restraints:

• Availability of Alternative Hemostasis Methods is Hampering the Topical Hemostat Market Growth

The presence of alternative hemostasis methods, including sutures, cauterization, and systemic haemostatic agents are major challenge that may impede Topical Hemostat Market growth. However, because of cost and familiarity, other commonly used traditional techniques of blood loss control are still the first-line hemostatic treatments by many surgeons and have not yet realized broad utilization for topical hemostats. Such competition can hinder market growth, especially in territories where healthcare systems are cost-conscious.

Topical Hemostat Market Opportunities:

• Growing Geriatric and High-Risk Patient Populations Drive Future Growth Opportunities for the Topical Hemostat Market

Increasing geriatric and at-high-risk patient populations are also fueling the market for advanced topical hemostats. Prompt and effective hemostasis is often necessary in elderly patients, in patients with bleeding disorders, with cardiovascular diseases, or to obviate post-surgical insults. This provides an opportunity to develop specialized, safe, and efficient hemostatic products for these high-risk populations to benefit surgical outcomes and reduce healthcare risk.

For instance, in May 2025, Innovation in advanced biomaterials, including collagen, chitosan, and fibrin-based hemostats, enhances clotting efficiency, tissue regeneration, and product differentiation, driving market growth.

Key Topical Hemostat Market Segment Analysis

• By type, thrombin held the largest share of around 29.69% in 2024, and the adhesives segment is expected to register the highest growth with a CAGR of 11.01%.

• By application, the general surgery segment dominated the market with approximately 35.53% share in 2024, while neurosurgery is expected to register the highest growth with a CAGR of 10.01%.

• By composition, collagen-based hemostats accounted for the leading share of nearly 45.94% in 2024, while thrombin-based hemostats are expected to register the highest growth with a CAGR of 10.02%.

• By end user, the hospitals segment led the market with about 68.96% share in 2024, while the ambulatory surgical centers are forecasted to grow the fastest at a CAGR of 9.76%.

By Type, Thrombin Leads the Market While Adhesives Register Fastest Growth

The thrombin segment accounted for the highest revenue share of approximately 29.26% in 2024, owing to its quick clotting feature and good ability to stop bleeding during complex operations. It has the potential to replace existing delivery methods with gels or patches, increasing the convenience of use. In comparison, the adhesives segment is anticipated to achieve the highest CAGR of nearly 11.01% during the 2025–2032 period, as they bond well and are easy to apply to heal wounds fast. The growth can be attributed to increasing minimally invasive surgeries, advances in biocompatible adhesive technologies.

By Application, the General Surgery Segment dominates, while the Neurosurgery Segment Shows Rapid Growth

The general surgery segment held the largest revenue share of approximately 35.53% in 2024, owing to its high volume across hospitals globally. One of the drivers for this market is the increasing number of surgeries necessitating successful bleeding control, ranging from abdominal to soft tissue procedures. On the other hand, the neurosurgery segment is predicted to grow at the strongest CAGR of approximately 10.01% during 2025–2032, owing to its delicate brain and spinal procedures are too risky for excessive bleeding. Advancements in minimally invasive neurosurgical techniques and, rising prevalence of a few kinds of diseases.

By Composition, Collagen-Based Hemostats Segment Lead, Thrombin-Based Hemostats, and Registers Fastest Growth

The collagen-based hemostats segment accounted for the largest share of the topical hemostat market with about 45.94%, owing to their good biocompatibility, quick clotting ability, and use across surgeries. Some of the determinants that drive the demand are that they are naturally sourced, perform absorption quickly, and provide high efficiency in controlling bleeding, particularly in orthopedic and cardiovascular surgeries. In addition, the thrombin-based hemostats segment is slated to grow at the fastest rate with a CAGR of around 10.02% throughout the forecast period of 2025–2032, as they are quick to form clots and highly efficient in major surgeries. Growth is driven by an increasing volume of minimally invasive and cardiovascular procedures. 

By End User, Hospitals Segment Lead, While the Ambulatory Surgical Centers Segment Grows the Fastest

The hospitals segment held the largest revenue share of around 68.96% in the topical hemostat market in 2024, driven by their large surgical procedure volumes. The main factors driving the market include the presence of high-quality healthcare infrastructure, a good number of well-experienced surgeons. On the flip side, the ambulatory surgical centers segment, however, is projected to register the highest CAGR of around 9.76% during the forecast period of 2025 - 2032, as a result of the growing trend towards outpatient surgeries. Factors including cost-effectiveness, less recovery time, and increasing patient preference for minimally invasive procedures drive the market.

Asia Pacific Urine Testing Cups Market Insights

The Asia Pacific segment is projected to witness the fastest CAGR of 10.16% during the forecast period of 2025–2032, owing to the faster development of healthcare infrastructure, increasing number of surgical procedures, and higher healthcare spending in emerging countries, including China, India, and Southeast Asia. Rising population and increasing middle class are propelling the demand for high-quality surgical care and effective hemostasis management. Furthermore, the market growth is supplemented by improving government initiatives to enhance healthcare access and growing awareness levels amongst medical professionals in terms of the advantages associated with topical hemostats.

North America Urine Testing Cups Market Insights

North America accounted for the highest revenue share of approximately 37.72% in 2024 of the Topical Hemostat Market, owing to the presence of key market players and high volumes of surgical procedures, resulting in the development of healthcare infrastructure in the region as well. Wide acceptance of novel hemostatic technologies among the establishment of extensively implemented innovative haemostats, and R&D investment in the region, are also factors leading to market growth. Moreover, increasing awareness among the concerned healthcare professionals for efficient bleeding control and a growing number of minimally invasive surgeries are some other factors propelling the growth pattern in the hemostatic agent products market.

Europe Urine Testing Cups Market Insights

The Europe Topical Hemostat Market is growing steadily due to a well-developed healthcare sector, high healthcare spending, and increasing surgical procedures. The increasing minimally invasive surgeries, a large number of reimbursement policies, and awareness among healthcare professionals for the hemostatic benefit are also contributing to the growth. Moreover, the growing base of R&D investments and the existence of leading market players expand Europe’s notable market position.

Latin America (LATAM) and Middle East & Africa (MEA) Urine Testing Cups Market Insights

The demand for Topical Hemostat is growing in Latin America, driven primarily by a growing trend towards urbanization, due to limited healthcare availability, low surgical procedure volumes, and poor healthcare spending in most regions. Moreover, the low recognition of sophisticated hemostatic products, insufficient availability of high-end medical technologies, and obstacles in reimbursement policies act as major impediments to market growth. Political instability and economic discrepancies also impede the extensive implementation, which is currently at a rather low rate compared with other regions globally.

Competitive Landscape for the Topical Hemostat Market:

Baxter International Inc. is pushing the boundaries of surgical care with a remedy for surgical bleeding, specialty hemostats and sealants, and a variety of products to control bleeding in vascular surgery, interventional cardiology, trauma, and other types of surgery. Baxter, with its extensive global reach, focuses on patient safety, efficiency, and outcomes, driving adoption in hospitals, surgicenters, and trauma centres globally.

• In June 2024, Baxter announced the expansion of its Floseal Hemostatic Matrix production capacity in the U.S. to meet rising global demand for bleeding management solutions. This strengthens its position in the surgical and trauma care markets.

Johnson & Johnson (Ethicon) offers a wide range of surgical products, including modern fibrin sealants and absorbable hemostatic agents. Utilizing the power of science and technology, Ethicon's hemostasis products help reduce surgery time and accelerate recovery, becoming the technological and clinical leader in advanced bleeding control.

• In March 2025, Ethicon received FDA clearance for its next-generation Surgicel Powder Absorbable Hemostat, designed for minimally invasive surgeries. The update enhances ease of application and precision in controlling intraoperative bleeding.

3M Company integrates biomaterials, wound care, and adhesive technologies to deliver hemostatic solutions that provide the quality and reliability you expect. Its product offering provides customer solutions that improve patient care in multiple surgical and tissue management specialties, including OR and ICU use, helping them be more efficient.

• In September 2024, 3M expanded its surgical wound and hemostat portfolio with a new advanced hemostatic patch launch in Europe, targeting trauma and emergency care markets with improved biocompatibility and faster clotting times.

Topical Hemostat Market Key Players:

Some of the Topical Hemostat Market companies are:

• Baxter International Inc.

• Johnson & Johnson

• 3M Company

• Medtronic Plc 

• Pfizer Inc

• B. Braun Melsungen AG

• CryoLife, Inc.

• Integra LifeSciences Holdings

• Stryker Corporation

• Cook Medical

• Arthrex, Inc.

• Confluent Surgical Inc.

• Hemostasis LLC

• Surgichem Inc.

• Porvair Sciences Ltd.

• Medi-Gel

• Balmed, Inc.

• Anika Therapeutics, Inc.

• Advanced Medical Solutions Group Plc

• Masimo Corporation